Alkermes (STU:8AK) Inventories, Finished Goods : €45 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Alkermes Inventories, Finished Goods?

Alkermes's quarterly finished goods declined from Sep. 2023 (€47 Mil) to Dec. 2023 (€42 Mil) but then increased from Dec. 2023 (€42 Mil) to Mar. 2024 (€45 Mil).

Alkermes's annual finished goods increased from Dec. 2021 (€31 Mil) to Dec. 2022 (€42 Mil) and increased from Dec. 2022 (€42 Mil) to Dec. 2023 (€42 Mil).

Alkermes Inventories, Finished Goods Historical Data

The historical data trend for Alkermes's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Inventories, Finished Goods Chart

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

11.85

22.65

31.07

41.66

42.32

Alkermes Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															47.89	48.52	47.24	42.32	45.35

Alkermes Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Alkermes (STU:8AK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

ALKS:USA 8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines